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WARNING 
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University in accordance with section 113P of the Copyright Act 1968 (Act). 
The material in this communication may be subject to copyright under the Act.  
Any further reproduction or communication of this material by you may be the subject of copyright 
protection under the Act. 
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           Charles Darwin University 
                    Final Examination  
 
 
PHA411 – Therapeutics C 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
The examination has THREE (A, B and C) Sections: 
 
Section A:  Multiple Choice Questions: Answer ALL forty (40) questions on the College 100-MCQ Answer Sheet 
provided.  Total marks allocated: Forty (40).  Suggested allocated time: 60 minutes 
 
Section B:  Extended Answer Questions:  Answer any 4 out of 5 questions.  Marks as indicated by lecturer.  Total 
marks allocated: Forty (40).  Suggested allocated time:  60 minutes. 
 
Section C:  Case Study Questions:  Answer ALL (2) questions.  Total marks allocated: Forty (40).  Suggested 
allocated time:  60 minutes 
 
Total = 120 marks 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
No calculators are permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 




3 x 16 Page Book 
1 x Scrap Paper 
College Multiple Choice Answer Sheet 
 
Family Name  
Given Name/s  
Student Number       
Teaching Period Semester 1, 2019 
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Section A 
Multiple Choice Questions 
Total No of Marks for this Section:  40 
 
This section should be answered on the College 100-MCQ Answer Sheet provided.  Please ensure that 
your name and student number have been written on the Answer sheet and placed in the completed 
Answer Booklet. 
Answer ALL forty (40) questions 
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Section B 
Extended Answer Questions 
Total No of Marks for this section:  40 
 
This section should be answered in the Answer Booklet provided. 
Answer any FOUR (4) questions only. 
 






(a) Identify FOUR (4) possible risk factors for erectile dysfunction (ED), and explain why these factors 
may contribute to ED. 
(Marks: 4) 
 
(b) List FOUR (4) major pharmacological classes of medications that can cause erectile dysfunction. 
 
 (Marks: 2) 
 
(c) Explain the mode of action of phosphodiesterase-5 (PDE5) inhibitors in managing ED.                      










(a) Name ONE (1) inherited syndrome which can pre-dispose a person to colorectal cancer. 
(Marks: 1) 
 




(c) What screening tests are available for early detection of colorectal cancer?  From where can 
patients access these? 
(Marks: 2) 
 
(d) Identify FOUR (4) host-related risk factors commonly associated with the development of malignant 
melanoma. 
(Marks: 2) 
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(e) Features of a mole or a lesion which indicate the need for further assessment, with the possibility of 







Patients receiving cytotoxic chemotherapy for treatment of cancer are at risk of chemotherapy induced 
nausea and vomiting (CINV). 
 
(a) Differentiate between acute CINV, delayed CINV and breakthrough CINV. 
      (hint: onset and duration). 
(Marks: 3) 
  
(b) Name THREE (3) drug classes which are highly effective in preventing CINV, and provide 




(c) Identify FOUR (4) other potential causes of nausea and vomiting in cancer patients which  
       need to be excluded before patients can be diagnosed with CINV. 
(Marks: 2) 
 
(d) Provide TWO (2) examples of chemotherapeutic agents which have high emetogenic risk                










(b) Explain the process of clinical staging of solid tumours and why this is important.   
(Marks: 3) 
 
(c) Give TWO absolute contraindications to menopausal hormone therapy. 
(Marks: 2) 
 
(d) What is meant by the term “unopposed estrogen” and what is the risk of giving this to a woman   
who still has her uterus? 
(Marks: 2) 
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(a) What is meant by “targeted treatment” in relation to oncology?  Provide FOUR (4) examples of 
targeted therapy molecules, their site of action (i.e. what they are targeting) and a type of cancer in 
which each targeted agent may be used. 
(Marks: 5) 
 
(b) In relation to palliative care, discuss FIVE (5) symptoms commonly experienced by patients in the 
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Section C 
Case Study Questions 
Total Number of Marks for this section: 40 
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  Suggested Time allocation for Section C:  60 mins 
 
 
Question 1 (20 marks) 
 
Gary, a 44-year-old man presented with complaints of extreme fatigue with painless, rubbery swelling in 
his cervical (neck) lymph nodes, occasional fevers, night sweats and unexplained weight loss of 6 kg from 
his 88kg frame in the past month.  Physical examination revealed several enlarged cervical (neck) lymph 
nodes but with no pharyngeal swelling or redness.  Further examination revealed marked 
lymphadenopathy in the right axillary (armpit) region and left inguinal (groin) nodes.  Gary’s medical 
history was unremarkable apart from glandular fever when he was 19 years old, and treatment for 
helicobacter pylori infection 5 years ago.  Excisional biopsy of a lymph node and immuno-phenotyping 
confirmed the diagnosis of diffuse large B-cell lymphoma (CD20+), a form of non-Hodgkin’s lymphoma 
(NLH), stage III1B. 
 
After consulting with his oncologist, Gary elected to receive combination chemotherapy R-EPOCH 
(rituximab, etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin). 
 
(a) Briefly discuss the aetiology and pathophysiology of NHL.  What is the main difference in the 
     diagnostic feature between NHL and Hodgkin’s Lymphoma (HL)? 
  (Marks: 5) 
 
(b) Is Gary’s lymphoma regarded as limited or advanced?  Explain why, with an explanation of    
      the subscript B. 
(Marks: 4) 
 
(c) What is the goal of treatment for Gary’s stage of NHL? 
(Marks: 1) 
 
(d) Describe the mechanisms of action of TWO (2) chemotherapeutic agents used to  
      treat Gary’s NHL (EPOCH - etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin).    




(e) Why is rituximab included in Gary’s chemotherapy regimen?  Include in your answer what  
      rituximab is targeting and the effect it has on cancer cells.    
(Marks: 4) 
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Question 2 (20 marks) 
Barbie, a 53 year old menopausal woman (BMI=30kg/m2), was referred to the oncology unit by her 
general practitioner after she developed an inverted nipple on her right breast.  Her mammogram and 
ultrasound showed a 3cm lesion, and further biopsies revealed a Grade 2 breast cancer with 2 positive 
sentinel lymph nodes.  (early stage IIB T2N1M0).   
She opted to undergo breast-conserving surgery (i.e. lumpectomy), and additional tests showed her 
tumour was estrogen and progesterone receptor (ER+/PR+) positive (i.e. HR+ve) and HER-2 negative. Her 
post-surgery treatment plan was to receive 4 cycles of doxorubicin 60mg/m2 IV and cyclophosphamide 
600mg/m2 IV infusion every 21 days, with adjuvant external beam radiation therapy to be commenced 4 
weeks after completing chemotherapy. 
Barbie’s medications on admission included: 
MEDICATION DOSE 
Estradiol 1mg + norethisterone 




1 puff bd 
Metformin tablet 500mg tds 
Salbutamol MDI 100mcg/dose 2-3 puffs prn 
Rosuvastatin tablet 10mg daily 
Perindopril tablet  5mg daily 
 
Barbie had 2 children, a son aged 20 and a daughter aged 17, both of whom were breastfed.  Her 
menarche occurred at 11 years of age.  Barbie was taking estradiol 1mg + norethisterone 0.5mg tablets 
for her menopausal symptoms for 4 years before her diagnosis of breast cancer.  Her blood pressure, 
asthma and diabetes were all well-controlled.   
Barbie was a smoker for 15 years but gave it up many years ago when she was pregnant with her first 
child. 
Barbie’s family medical histories include; 
• Mother passed away from breast cancer 30 years ago 
• Father died from heart attack 6 years ago 
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(b) In relation to breast cancer, explain what is meant by “sentinel lymph node” biopsy?  Why is this 
performed, where are these lymph nodes located and what is the advantage in not removing all the 
lymph nodes adjacent to the breast? 
(Marks: 4) 
(c) Explain what is meant by “hormone positive (HR+) breast cancer” and suggest adjuvant endocrine 
agents which may be considered beneficial in managing Barbie’s breast cancer.  In your answer, 
provide TWO (2) examples, elaborate on how they work, and for how long they will likely be taken.  
What are TWO (2) common side effects of each agent? 
(Marks: 6) 
(d) What is the goal of treatment for Barbie’s current stage of breast cancer?  
(Marks: 2) 





End of Section C 
 
End of Examination 
 
 
 
